-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The association between serum uric acid (SUA) and cardiovascular disease risk is clear.
, the effect of SUA levels on the risk of venous thrombosis (VTE) recurrence is not yet clear.
recently, a study published in Journal of Thrombosis and Haemostasis, an authoritative journal of thrombosis and clotting diseases, looked at the link between SUA levels and the risk of VTE recurrence.
researchers conducted a single-center prospective study of 280 patients who had previously developed VTE and had completed oral anticoagulants to assess the relationship between SUA levels at hospital and the risk of VTE recurrence (average follow-up 71.1±29.2 months).
patients are strated according to the distribution of SUA tri-digits at baseline (tri-digit critical value: I≤4.37 mg/dl, II≤4.38-5.54 mg/dl, III≥5.55 mg/dl).
50 VTE recurrence events occurred during follow-up, Kaplan-Meyer survival analysis showed that subjects with a lower tri-level of SUA had a significantly lower risk of VTE recurrence (p.003).
there was no significant difference between patients with SUA in the second and third digits.
multiple Cox regression analysis showed that patients with higher SUA tritesals had a approximately three-fold increased risk of VTE recurrence (HR of 3.04, 95% CI of 1.15-8.05, p-0.025) compared to subjects with SUA≤4.37.
addition, the researchers observed that for every additional unit (mg/dl) added to SUA, the adjusted risk of VTE recurrence increased by 30% (HR is 1.30, 95% CI is 1.01-1.22, p=0.040).
, the increase in SUA levels is associated with an increased risk of VTE recurrence, independent of traditional risk factors.
.